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Introduction {#sec1}
============

All eutherians (placental mammals) experience contraction of the uterus and discomfort during parturition. Although this discomfort is universal in eutherians, it appears to be most marked in humans ([@bib25]). The severity of labor pain is considered a consequence of positive sexual selection in modern humans (with females seeking the cleverest mate), which has led to the human brain (and head) being three times the relative size of our nearest primate relatives ([@bib42]). Despite neoteny (birth of offspring in a relatively immature state), this imposes a need to deliver a large neonatal head through the birth canal, causing labor pain ([@bib15]). Although labor pain is clearly linked to uterine contractions and cervical distension, the generation of this visceral signal and the sensory afferents involved are poorly understood ([@bib21]).

Although there are well-established ethnic, social, and cultural factors that influence the experience and expression of pain during labor ([@bib53]), broader genetic effects on labor pain may also exist. For example, women with the very rare Mendelian disorder congenital insensitivity to pain due to bi-allelic non-functional mutations in *SCN9A* (MIM: [243000](243000){#intref0010}) do not report labor pain or require analgesics during labor ([@bib16]). *SCN9A* encodes for the voltage-gated sodium channel Na~V~1.7, expressed selectively in nociceptive and autonomic neurons, and mutations in *SCN9A* have well-documented roles in causing extremely painful or painless phenotypes ([@bib1]). The painlessness conferred by loss-of-function *SCN9A* mutations is clearly maladaptive and can be associated with severe injury during human parturition ([@bib52]).

Our aim here was not to discover very rare Mendelian mutations that cause extreme painlessness, for example, congenital insensitivity to pain. Instead, the genetic analyses employed here are optimized for investigation of phenotypes that require an environmental trigger and genetic predisposition and that will not appear to have a Mendelian inheritance pattern unless the triggering event is frequent ([@bib45]). This approach is suited for the study of labor pain, which may be considered nociceptive in nature, with parturition serving as a visceral stimulus. We sought to identify functional SNP alleles that are over- or under-represented in a cohort of women who did not request or use analgesics that were available and offered to them during labor: an observable behavioral phenotype considered highly unusual in hospital maternity units in the United Kingdom, particularly for spontaneous delivery of term nulliparous women. Quantitative sensory testing, performed with our study cohort, suggests a general increase in pain thresholds and tolerance compared with controls, but only the increase in the cuff pressure pain threshold survived statistical significance after adjustment for multiple comparisons. We next assessed the allele frequencies of all (genome-wide) protein-changing single nucleotide polymorphisms (SNPs) in these women compared with population frequencies. We found that the voltage-gated potassium channel (K~V~) modifier *KCNG4* (K~V~6.4) SNP rs140124801 rare allele c.1255G\>A p.(Val419Met) was over-represented. Finally, we demonstrate the effects of this rare K~V~6.4-Met419 variant on sensory neuron excitability and reveal a mechanism through which uterine nociception and, hence, labor pain can be attenuated in humans.

Results {#sec2}
=======

Identifying Women Who Did Not Require Analgesics during Labor as Nulliparous Parturients: The Test Cohort {#sec2.1}
---------------------------------------------------------------------------------------------------------

1,029 potential subjects were identified from 8 maternity units in the United Kingdom over a 3-year period. Each potential subject was invited to contact researchers, as chronologically ascertained. 383 women responded and were screened via telephone ([Figure S1](#mmc1){ref-type="supplementary-material"}A). Key inclusion criteria were healthy Caucasian women who experienced term (beyond 37-week gestation) and spontaneous vaginal delivery as nulliparous parturients without any use or request of any form of systemic or regional analgesia (spinal or epidural). We excluded women who had major diseases or co-morbidities that are known to influence labor pain or pain in general. 189 women met the full eligibility criteria ([Table S1](#mmc1){ref-type="supplementary-material"}), returned written consent, and donated 10 mL of blood (collected at their local hospital) or 2 mL of saliva, sent via postal service, from which DNA was extracted.

Of the women who donated DNA, 39 consented to a subsequent study of psychometrics and quantitative sensory testing. These women comprised a subset of the genetic discovery cohort for a case-controlled study ([Figure S1](#mmc1){ref-type="supplementary-material"}B). For the control cohort, we recruited 33 women who were matched in age at delivery of the firstborn and location of maternity service but who used analgesics during labor and delivery of their firstborn ([Table S1](#mmc1){ref-type="supplementary-material"}). There were no significant differences in the means of newborn weight or head circumference between test and control cohorts ([Table 1](#tbl1){ref-type="table"}).Table 1Key Characteristics of the Test Cohort of Women Who Did Not Request or Require Analgesics during Nulliparous Term Spontaneous Labor and Control Subjects Who DidCharacteristics (at Delivery of First-Born)Test CohortControl Cohortp Unadjustedp Adjusted^∗^CI5CI95nMeanSDnMeanSDAge (years)3932.834.183331.943.980.33N/A−2.730.93Head circumference of newborn (cm)2634.000.98^+^2434.460.970.10N/A−0.101.01Weight of newborn (g)383362434.1333384419.20.83N/A−180.90224.76Characteristics (at Research Visit)Test CohortControl Cohortp Unadjustedp Adjusted^∗^CI5CI95nMeanSDnMeanSDAge (years)3936.264.183336.454.110.62N/A−1.482.46Upper arm diameter at assessment (cm)3928.543.603329.233.630.43N/A−1.032.41Sensory and Pain ThresholdsCold detection (°C)3930.450.933330.350.950.79N/A−0.420.25Warmth detection (°C)3934.430.993334.970.870.0020.0120.281.05Cuff pressure detection (mmHg)3928.447.793327.108.380.51N/A−5.001.33Cold pain (°C)3911.648.263316.889.030.020.1141.179.73Heat pain (°C)3944.082.853342.363.400.0180.103−2.92−0.27Cuff pressure pain (mmHg)39166.754.7433113.0342.960.000020.00012−77.03−30.13Pain Tolerance (Cold Immersion)Pre-immersion hand temperature (°C)3430.461.953330.821.660.42N/A−0.531.24Post-immersion hand temperature (°C)33[b](#tblfn1){ref-type="table-fn"}17.924.723320.513.540.020.120.404.60Latency to hand withdrawal (s)36[b](#tblfn1){ref-type="table-fn"}77.0371.823344.1155.730.030.14−38.0−0.0000Peak pain occurrence (0--100 mm)35[b](#tblfn1){ref-type="table-fn"}80.1927.393379.0428.990.71N/A−5.504.00Peak pain intensity (0--100 mm)35[b](#tblfn1){ref-type="table-fn"}54.2917.263365.8213.200.0040.023.2018.1SFMPQ (sensory)368.473.823310.974.000.0100.0490.624.38SFMPQ (affective)361.001.53331.241.350.26N/A−0.000020.99995[^4][^5][^6]

Cognitive and Emotional Functions Are Normal in the Test Cohort {#sec2.2}
---------------------------------------------------------------

Psychometrics, comprising validated questionnaires and computerized cognitive assessments, were employed to quantify mood, beliefs, and personality traits that can influence pain in experimental or clinical settings. The questionnaires included were the Hospital Anxiety and Depression Scale (HADS; [@bib56]), Pain Catastrophizing Scale (PCS; [@bib46]), Multidimensional Health Locus of Control Scale (MHLC; [@bib44]), and Life Orientation Test -- Revised (LOTR; [@bib41]). Computerized cognitive assessments were implemented in CANTAB (Cambridge Cognition, UK; [@bib37]). There were no significant differences in psychological or cognitive measures between the control and test cohorts ([Table S2](#mmc1){ref-type="supplementary-material"}).

Experimental Pain Thresholds and Tolerance Are Increased in the Test Cohort {#sec2.3}
---------------------------------------------------------------------------

Next, we quantified sensory detection and pain thresholds to cold, heat, and mechanical pressure. Thermal stimuli were delivered using a skin thermode applied to the forearm. Mechanical pressure was exerted via compression of the upper arm by a sphygmomanometer cuff. There were no significant differences in the detection thresholds of cold or cuff pressure in the test and control cohorts to suggest sensory deficits or impairments pertaining to those stimuli in the test cohort ([Table 1](#tbl1){ref-type="table"}; [Figure S2](#mmc1){ref-type="supplementary-material"}A). Warmth detection thresholds were very slightly but significantly lower in the test cohort compared with controls (0.54°C difference), but all individual values fell within established norms for the general population ([@bib38]).

The test cohort had increased pain thresholds to heat, cold, and cuff pressure at an unadjusted significance level of p \< 0.05 compared with controls ([Figure S2](#mmc1){ref-type="supplementary-material"}A). There was a very striking increase of over 50 mmHg in the cuff pressure pain threshold (p = 0.00002, uncorrected; p = 0.00012, Sidak's correction; [Table 1](#tbl1){ref-type="table"}), suggesting that this characteristic might be relevant to the lack of analgesic requirement during nulliparous labor in the test cohort.

During testing for tolerance to pain from immersion of a hand in cold water (3°C), compared with controls, the test cohort showed increased hand withdrawal latency (p = 0.03, uncorrected), lower post-immersion skin temperatures (p = 0.02, uncorrected), and a lower peak intensity of pain on the 100-mm visual analog scale (VAS) (p = 0.004, uncorrected; p = 0.02, Sidak's correction) upon later assessment ([Figure S2](#mmc1){ref-type="supplementary-material"}B). The short-form McGill pain questionnaire ([@bib27]) revealed lower scores (p = 0.01, uncorrected; p = 0.049, corrected) for the sensory descriptors for the test group. There was no between-group difference in scores related to the affective aspects of the experimentally induced pain experienced (p = 0.26). These individual results do not survive statistical correction for multiple comparisons; further work is necessary to determine whether cold pain tolerance differs between the test and control cohorts.

The Rare Allele of rs140124801 in *KCNG4* Is Over-represented in the Test Cohort {#sec2.4}
--------------------------------------------------------------------------------

In 158 of the 189 women who did not require analgesics during their first labor, we obtained enough high-quality DNA for molecular genetic analysis ([Figure S1](#mmc1){ref-type="supplementary-material"}). The chronologically first 100 such women (by date of banking DNA) constituted a discovery cohort ([Figure 1](#fig1){ref-type="fig"}A); the next 58 women constituted our replication cohort. Those in the discovery cohort had exome sequencing, from which we used the bam and bam.bai files for genome-wide SNP allele frequency assessment using the fSNPd program ([@bib45]). The replication cohort of 58 was assessed only for SNP rs140124801 alleles using Sanger sequencing of genomic DNA.Figure 1Molecular Genetics of *KCNG4* SNP rs140124801 and Analysis of K~V~2.1 Inactivation Properties(A) Summary of the genetic analysis. The resultant finding is of the SNP rs140124801 in *KCNG4*. Inset: electrophoretograms showing the alleles.(B) The nucleotide sequence of the SNP rs140124801 (NM_1.NM_172347.2), showing the altered GTG codon (boldface) and the rare allele (red). Amino acids 416--423 of K~V~6.4 (NP_758857.1) are shown below their nucleotide codons. The selectivity filter is shown in boldface, and the wild-type Val-419 is shown above Met-419.(C) Evolutionary conservation of human K~V~6.4 positions 408--426: rs140124801 alleles and representative proteins of each human K~V~ class and of K~V~6.4 in vertebrates. Invariant amino acids are capitalized. The selectivity filter TVGYG is shown in yellow and the conserved aliphatic region in gray.(D--F) Representative current recordings to determine K~V~2.1 (D), K~V~2.1/K~V~6.4 (E), and K~V~2.1/K~V~6.4-Met419 (F) steady-state inactivation properties. The applied voltage protocol is illustrated above (D). Vertical scale bar, 10 nA; horizontal scale bar, 0.5 s. Green traces indicate currents recorded during the −40 mV conditioning step.(G) Voltage dependence of steady-state inactivation of K~V~2.1 (gray filled circles, n = 9), K~V~2.1/K~V~6.4 (white squares, n = 12), and K~V~2.1/K~V~6.4-Met419 (black squares, n = 15). Symbols represent mean values, and error bars indicate SEM. Solid lines represent the Boltzmann fitted curves.

Our discovery cohort analysis identified one ion channel SNP where the allele frequency was altered compared with the reference ([Figure 1](#fig1){ref-type="fig"}A; [Table S3](#mmc2){ref-type="supplementary-material"}). The rare allele of rs140124801 in *KCNG4* was over-represented, being found in 3 instances, whereas 0.7 instances were expected (q = \< 0.05, false discovery rate \[FDR\] corrected). We examined the individual exome results using the Integrated Genome Viewer (<https://software.broadinstitute.org/software/igv/>) and found that 3 individuals were heterozygous for the rare allele and confirmed this by Sanger sequencing. In the replication cohort, we found one further rare SNP rs140124801 heterozygote. For the total cohort of 158 women not requiring analgesia during their first delivery, there were 4 heterozygotes carrying the rs140124801 rare allele compared with an expected 1.1 (chi-square two-tail with Yates correction = 4.779, p = 0.0288; [Figure S1](#mmc1){ref-type="supplementary-material"}A).

In case-controlled studies, we further explored whether 3 of the individuals who possess the rare *KCNG4* allele had significantly different experimental pain thresholds compared with those who did not (n = 69; [Figure S1](#mmc1){ref-type="supplementary-material"}B). We investigated pain thresholds for heat, cold, and cuff pressure and found that the rare *KCNG4* allele was associated with a significantly increased cuff pressure pain threshold (p = 0.0029, uncorrected; p = 0.009, Sidak's correction; [Table S4](#mmc1){ref-type="supplementary-material"}). Although the sample size here is very small because of the rarity of the *KCNG4* allele being examined, the finding suggests that an effect of this rare allele is to increase the experimental cuff pressure pain threshold in humans. The experimental cuff pressure pain remains significantly increased in the test cohort (even with the 3 rare allele cases excluded, compared with the control group (p = 0.0029, uncorrected; p = 0.009, Sidak's correction; [Table S4](#mmc1){ref-type="supplementary-material"}) suggesting that the cuff pressure pain threshold might be relevant to labor pain. Although there are clearly other reasons for an increased cuff pressure pain threshold in individuals who do not carry the rare *KCNG4* allele, these data suggest that the rare allele of *KCNG4* may be related to the lack of analgesic requirement for the 3 subjects we identified in this study.

The p.Val419Met Change in K~V~6.4 Impairs the Function of K~V~2.1 Heterotetramers {#sec2.5}
---------------------------------------------------------------------------------

The rare allele of rs140124801 in *KCNG4* causes the missense change p.Val419Met encoding K~V~6.4 (from here on referred to as K~V~6.4-Met419; [Figures 1](#fig1){ref-type="fig"}A and 1B). K~V~s are tetrameric complexes, with each subunit having six transmembrane domains (S1--S6). K~V~6.4 is a member of the electrically silent group of K~V~ subunits, which cannot form functional plasma membrane-expressed homotetramers but, instead, act as modulators of K~V~2 subunits ([@bib5]). Indeed, K~V~6.4 is known to heterotetramerize with K~V~2.1 in a 1:3 stoichiometry ([@bib8]). Valine 419 is in the pore-forming S5-S6 linker and is part of the highly conserved K^+^ selectivity filter consensus sequence (T**V**GYG; [Figure 1](#fig1){ref-type="fig"}C), in which the equivalent position is always occupied by a branched-chain amino acid. Although originally thought to be relatively rigid, this structure is also involved in open-pore or C-type inactivation because subtle rearrangements block the conductive path of K^+^ ions ([@bib13]). It therefore seemed likely that rs140124801 might affect K^+^ selectivity and/or inactivation; thus, we studied the electrophysiological properties of K~V~6.4-Met419 in complex with K~V~2.1 compared with the most frequent *KCNG4* allele, which possesses a valine at position 419 (K~V~6.4) in complex with K~V~2.1.

We used HEK293 cells as a heterologous expression system that does not express significant endogenous K~V~ currents ([Figure S3](#mmc1){ref-type="supplementary-material"}). As expected, overexpression of K~V~6.4 or K~V~6.4-Met419 alone did not produce measurable K^+^ currents ([Figure S3](#mmc1){ref-type="supplementary-material"}E). However, in cells expressing K~V~2.1 alone, outward currents were observed that were activated by potentials more positive than −40 mV and displayed slow inactivation ([Figure S3](#mmc1){ref-type="supplementary-material"}A). Co-expression of K~V~2.1 with K~V~6.4 produced outward currents with similar kinetics ([Figure S3](#mmc1){ref-type="supplementary-material"}D), but we observed a small shift in the voltage of half-maximal activation (V~0.5~ act) to more negative potentials. This shift was not observed when K~V~6.4-Met419 was co-expressed with K~V~2.1 ([Figure S3](#mmc1){ref-type="supplementary-material"}D). The current amplitude generated was similar between wild-type K~V~6.4 or K~V~6.4-Met419 co-expressed with K~V~2.1 ([Figure S3](#mmc1){ref-type="supplementary-material"}E), showing that expression of K~V~6.4-Met419 does not negatively regulate maximal current flux, over wild-type K~V~6.4, a factor that would affect sensory neuron excitability ([Figure S3](#mmc1){ref-type="supplementary-material"}E). The slope factors of the Boltzmann fits did not significantly differ between the 3 groups (K~V~2.1: k = 9.5 ± 0.8, n = 13; K~V~2.1 + K~V~6.4: k = 15.9 ± 1.7, n = 14; K~V~2.1 + K~V~6.4-Met419: k = 11.0 ± 0.8, n = 13; one-way ANOVA, p \> 0.05). Furthermore, the reversal potential was not significantly different between the groups ([Figure S3](#mmc1){ref-type="supplementary-material"}F).

Similar to previous reports ([@bib7]), co-expression of K~V~6.4 resulted in a large hyperpolarizing shift in the voltage dependence of inactivation by \~30 mV compared with K~V~2.1 homomeric currents ([Figures 1](#fig1){ref-type="fig"}D, 1E, and 1G). This hyperpolarizing shift was not observed when K~V~2.1 was co-expressed with K~V~6.4-Met419 ([Figures 1](#fig1){ref-type="fig"}F and 1G). There was, however, no significant difference in the slope factor of inactivation curves between the three groups (K~V~2.1: k = 9.8 ± 1.4, n = 9; K~V~2.1 + K~V~6.4: k = 13.6 ± 2.4, n = 12; K~V~2.1 + K~V~6.4-Met419: k = 12.2 ± 1.2, n = 15; Kruskal-Wallis test, p \> 0.7) or in their time courses of recovery from inactivation ([Figure S3](#mmc1){ref-type="supplementary-material"}G). These data suggest loss of K~V~6.4 function as a result of the p.Val419Met mutation.

K~V~6.4-Met419 Does Not Traffic with K~V~2.1 to the Plasma Membrane {#sec2.6}
-------------------------------------------------------------------

As discussed above, K~V~6.4 forms heterotetramers with K~V~2.1 with altered biophysical properties compared with homotetrameric K~V~2.1 channels ([@bib4]; [Figures 1](#fig1){ref-type="fig"}D--1G; [Figure S3](#mmc1){ref-type="supplementary-material"}). In addition, K~V~6.4 is retained in the endoplasmic reticulum in the absence of K~V~2.1, requiring expression of K~V~2.1 for trafficking to the cell membrane ([@bib33]). We thus tested whether the p.Val419Met alteration might affect trafficking of K~V~6.4. For this, K~V~6.4 was cloned into a pcDNA3-based vector containing a CMV-polioIRESmCherry expression cassette and tagged with hemagglutinin (HA), and then the p.Val419Met alteration was introduced. K~V~2.1 had been cloned previously into pCAGGS-IRES2-nucEGFP, which displays a nuclear GFP signal upon transfection. To assess membrane localization, HEK293 cells were co-transfected with K~V~2.1 and K~V~6.4 and stained for HA-tagged K~V~6.4, with co-expressing cells identified by mCherry and nuclear GFP signal. K~V~6.4 was retained within the cytoplasm in the absence of K~V~2.1 expression but displayed a striking shift to the cell membrane upon co-transfection with K~V~2.1 ([Figure 2](#fig2){ref-type="fig"}A). There was no appreciable difference in the localization of K~V~6.4-Met419 in the absence of K~V~2.1, but in the presence of K~V~2.1 and in contrast to the wild-type protein, K~V~6.4-Met419 was retained intracellularly and showed no membrane localization ([Figure 2](#fig2){ref-type="fig"}A). Importantly, expression of K~V~6.4-Met419 in HEK293 cells showed only a modest reduction in steady-state stability compared with wild-type K~V~6.4, and this was not affected by co-expression with K~V~2.1 ([Figures 2](#fig2){ref-type="fig"}B and 2C).Figure 2p.Val419Met Blocks K~V~6.4 from Reaching the Plasma Membrane Independent of Changes in Steady-State Expression(A) Immunofluorescence analysis of K~V~6.4 localization. In the absence of K~V~2.1, K~V~6.4 was retained in the cytoplasm (white channel, top panel) and trafficked to the cell membrane in the presence of K~V~2.1 (white channel, second row). In contrast, HA-tagged K~V~6.4-Met419 did not localize to the cell membrane in the absence or presence of K~V~2.1 expression (white channels in the third and fourth rows). Expression of K~V~2.1 is demonstrated by the presence or absence of green nuclei, expression of K~V~6.4 is displayed directly by HA tag in the white channel, and expression of the IRES vector expressing K~V~6.4 is displayed by the presence of the mCherry signal in the red channel. Graphs adjacent to each row display the intensity of the K~V~6.4 HA signal along the red line in each respective white channel; note membrane-localized peaks only in K~V~6.4 when co-expressed with K~V~2.1. Scale bars indicate 10 μm.(B) HA-tagged K~V~6.4 was transiently expressed in the presence or absence of K~V~2.1. There was a modest reduction in steady-state stability for K~V~6.4-Met419 compared with K~V~6.4.(C) Stability as assessed by densitometry of HA compared with mCherry as a control of transfection efficiency. Error bars indicate standard error. Unpaired t test (\*p = 0.04).

K~V~6.4 Is Expressed in Nociceptors that Innervate the Uterus {#sec2.7}
-------------------------------------------------------------

Altered K~V~ function produces dramatic effects upon sensory neuron excitability; K~V~7 openers ([@bib34]) and K~V~2 inhibitors ([@bib48]) decrease and increase sensory neuron excitability, respectively. We hypothesized that expression of K~V~6.4-Met419 within sensory neurons innervating the uterus would alter neuronal excitability and contribute to impaired nociception. We first investigated the expression of *Kcng4* and *Kcnb1* in mouse uterine sensory neurons using single-cell qRT-PCR of sensory neurons retrogradely labeled with fast blue from the uterus ([Figure 3](#fig3){ref-type="fig"}A). Sensory innervation of the mouse uterus possesses two distinct peak densities within thoracolumbar (TL) and lumbosacral (LS) spinal segments ([@bib17]). Therefore, fast blue-positive uterine sensory neurons were collected from dorsal root ganglia (DRG) isolated from vertebra levels T12--L2 and L5--S2. These had an average cell diameter of 31.0 ± 0.7 μm (n = 89), which is in broad agreement with studies investigating sensory neurons innervating the uterus and other visceral organs, including the distal colon ([@bib17]; [@bib18]). Most uterine neurons expressed *Kcnb1* (TL, 82% \[36 of 44\]; LS, 66% \[30 of 45\]), and *Kcng4* mRNA was detected in a subset of uterine neurons from both spinal pathways (TL, 43% \[19 of 44\]; LS, 24% \[11 of 45\]; [Figure 3](#fig3){ref-type="fig"}B). The average cycle threshold (CT) value for *Kcng4*-expressing neurons was higher than that of *Kcnb1* (27.2 versus 16.3; [Figure S4](#mmc1){ref-type="supplementary-material"}), which may indicate relatively lower expression levels. Importantly, all but one LS neuron co-expressed *Kcng4* with *Kcnb1*, suggesting that these two K~V~ subunits are predominantly present in the same uterine sensory neuron subset. We also assessed the mRNA expression of the nociceptor markers transient receptor potential vanilloid 1 (*Trpv1*) and voltage-gated sodium channel 1.8 (S*cn10a*). In *Kcng4*-positive uterine sensory neurons, *Trpv1* mRNA was present in 100% of TL and 91% of LS neurons and *Scn10a* in 95% of TL and 91% of LS neurons, suggesting that K~V~6.4 is expressed by a population of neurons capable of transducing noxious stimuli ([Figure 3](#fig3){ref-type="fig"}B).Figure 3*Kcng4* Is Coexpressed with *Kcnb1* in Mouse Uterine Sensory Neurons, and Expression of K~V~6.4-Met419 in Mouse Sensory Neurons Increases the Threshold for Action Potential Discharge Compared with K~V~6.4(A) Uterine sensory neurons were retrogradely labeled using fast blue and harvested following dissociation. Scale bar, 40 μm.(B) Co-expression analysis of TL (T12--L2, n = 44 cells) and LS (L5--S2, n = 45 cells) uterine sensory neurons expressing transcripts for *Kcng4*, *Kcnb1*, *Trpv1*, and *Scn10a*. Each segment in the wheel diagram is representative of a single cell, with a colored segment signifying positive expression.(C and D) Representative current recordings to determine the voltage dependence of steady-state inactivation of the stromatoxin-1 (ScTx)-sensitive *I*~K~ elicited by the inset voltage protocol in the absence (C) and presence (D) of 100 nM ScTx. Green traces indicate currents recorded during the −40-mV conditioning step.(E) The ScTx-sensitive *I*~K~ was obtained by subtraction of (D) from (C).(F) Inactivation curves for the ScTx-sensitive *I*~K~ for neurons transfected with K~V~6.4 (n = 8) or K~V~6.4-Met419 (n = 7). Both datasets were fit with a sum of two Boltzmann functions. The midpoints of the second components of these fits are plotted as light dashed (K~V~6.4) or heavy dashed (K~V~6.4-Met419) lines. Each point and error bars indicate mean ± SEM.(G) Representative current clamp recordings of neurons of comparable capacitance transfected with K~V~6.4 or K~V~6.4-Met419, showing action potentials evoked by ramp injection of current (0--1 nA, 1 s). The thresholds for action potential discharge are annotated with light dashed (K~V~6.4) or heavy dashed (K~V~6.4-Met419) lines.(H and I) Summary data of action potential thresholds obtained from neurons transfected with K~V~6.4 or K~V~6.4-Met419 and untransfected controls obtained via (H) a ramp protocol (0--1 nA, 1 s) or (I) a step protocol (+10 pA, 50 ms). Red points represent cells that responded to 1 μM capsaicin in voltage-clamp mode.Both recordings in (G) were from cells that were capsaicin responders. Bars indicate mean values, error bars indicate SEM, n = 6-10, ^∗^p \< 0.05, one-way ANOVA with Bonferroni's correction for multiple tests.

K~V~6.4-Met419 Causes Loss of Modulatory Function of K~V~2.1 and Decreases Neuronal Excitability in DRG Sensory Neurons {#sec2.8}
-----------------------------------------------------------------------------------------------------------------------

Given the high co-expression of *Kcng4* with *Kcnb1* in uterine sensory neurons, we next characterized the effect of K~V~6.4 and K~V~6.4-Met419 on sensory neuronal function. We recorded outward delayed rectifier K^+^ currents (*I*~K~) and investigated the effect of transient transfection of K~V~6.4 or K~V~6.4-Met419 on the stromatoxin-1 (ScTx)-sensitive *I*~K~; ScTx is a gating modifier of K~V~2.1, K~V~2.2, and K~V~4.2 that effectively blocks these channels ([@bib14]) as well as K~V~2.1 heterotetramers formed with silent K~V~ subunits ([@bib55]). Through subtraction of *I*~K~ in the presence of ScTx from total *I*~K~ in the absence of ScTx, we isolated the ScTx-sensitive *I*~K~, which is predominantly dependent on K~V~2 channels ([Figures 3](#fig3){ref-type="fig"}C--3F). A diverse and heterogenous population of K~V~2 and silent K~V~ subunits is expressed in sensory neurons ([@bib6]; [@bib18]; [@bib54]), and previous studies suggest that silent K~V~ subunits only heterotetramerize with K~V~2 subunits but not K~V~1, K~V~3, and K~V~4 subunits ([@bib4]). Therefore, we predicted that wild-type K~V~6.4 heterotetramerization with K~V~2.1 in sensory neurons would produce functional channels but with a hyperpolarized shift in the voltage dependence of inactivation compared with homotetrameric K~V~2.1 channels, as we ([Figures 1](#fig1){ref-type="fig"}D--1G) and others observed previously in HEK293 cells ([@bib4]). In contrast, we hypothesized that the K~V~6.4-Met419 subunit would be unable to evoke such a hyperpolarizing shift in the voltage dependence of inactivation.

By transfecting mouse sensory neurons with K~V~6.4 or K~V~6.4-Met419, we attempted to bias available K~V~2.1 into heterotetramers with K~V~6.4 subunits, increasing the probability of recording the contribution of K~V~2.1/K~V~6.4 heterotetramers to ScTx-sensitive *I*~K~. In K~V~6.4 and K~V~6.4-Met419 experiments, addition of ScTx led to a maximum reduction in outward K^+^ current at a 20-mV step potential, which did not differ significantly (K~V~6.4, 52.7% ± 3.8%; K~V~6.4-Met419, 45.1% ± 7.7%; Student's t test, p = 0.37; [Figures 3](#fig3){ref-type="fig"}C--3E). The voltage dependence of ScTx-sensitive *I*~K~ activation was similar for neurons transfected with the K~V~6.4 or K~V~6.4-Met419 subunit (voltage of half-maximal activation \[V~1/2~\] = −5.4 ± 1.8 mV versus −9.8 ± 1.1 mV, and k = 8.6 ± 1.5 versus 8.9 ± 0.9, respectively; [Figure S5](#mmc1){ref-type="supplementary-material"}). As observed previously ([@bib6]), the voltage dependence of ScTx-sensitive *I*~K~ inactivation for K~V~6.4 and K~V~6.4-Met419 experiments was multifactorial and fitted with a sum of two Boltzmann functions. In neurons transfected with K~V~6.4, the midpoint of the first component was −0.8 ± 29.5 mV, which likely correlates with homotetrameric K~V~2.1 currents. The second component possessed a midpoint of inactivation of −60.2 ± 6.6 mV (n = 8), a current that is likely a function of heterotetrameric K~V~2/silent K~V~ channels or differentially phosphorylated K~V~2 channels and in line with what others have reported for the second component of *I*~K~ in DRG neurons in the presence of ScTx ([@bib6]). Importantly, expression of K~V~6.4-Met419 led to a significant depolarizing shift in the second component of the voltage dependence of inactivation (−33.8 ± 2.1 mV, n = 7, unpaired t test, p = 0.003; [Figure 3](#fig3){ref-type="fig"}F), whereas the first component, attributed to homotetrameric K~V~2.1 *I*~K~, remained unchanged (−36.2 ± 3.3 mV, unpaired t test, p = 0.29; [Table S5](#mmc1){ref-type="supplementary-material"}A).

We assessed the functional consequences on neuronal excitability of such a shift in the availability of K~V~2 channels toward more depolarized potentials through current clamp experiments. The threshold for action potential discharge was assessed for neurons transfected with K~V~6.4 or K~V~6.4-Met419 as well as neurons that exhibited no mCherry fluorescence from cultures exposed to either plasmid (considered untransfected). Neurons transfected with K~V~6.4-Met419 exhibited a higher threshold than those overexpressing K~V~6.4 or untransfected neurons during injection of a progressively depolarizing current (ramp protocol: 0--1 nA, 1 s); however, only the difference between K~V~6.4-Met419 and K~V~6.4 reached statistical significance (K~V~6.4, 91.6 ± 16.7 pA versus K~V~6.4-Met419, 248.6 ± 50.3 pA, ANOVA with Bonferroni multiple comparisons, p = 0.018; untransfected (Untran.), 112.5 ± 32.5 pA versus K~V~6.4-Met419, 248.6 ± 50.3 pA, p = 0.087; [Figures 3](#fig3){ref-type="fig"}G and 3H). A higher current was also required to evoke action potentials when the threshold was assessed with a step protocol (+10 pA, 50-ms injections starting at 0 pA). Similarly, only the difference between K~V~6.4 and K~V~6.4-Met419 proved to be significant (K~V~6.4, 61.1 ± 12.2 pA versus K~V~6.4-Met419, 172.0 ± 34.4 pA, ANOVA with Bonferroni multiple comparisons, p = 0.012; Untran., 88.3 ± 13.8 pA versus K~V~6.4-Met419 172.0 ± 34.4 pA, p = 0.124; [Figure 3](#fig3){ref-type="fig"}I). The ability of neurons to respond to capsaicin was also examined to identify putative nociceptors (i.e., those expressing *Trpv1*), but no obvious pattern regarding the subpopulations of nociceptive and non-nociceptive neurons within each group could be observed. Analyses of other action potential parameters revealed no further differences between neurons transfected with either K~V~6.4 construct or untransfected cells ([Table S5](#mmc1){ref-type="supplementary-material"}B). Taken together, these findings demonstrate that sensory neurons expressing K~V~6.4-Met419 are less excitable than those transfected with K~V~6.4. We thus postulate that uterine primary afferent input into the pain pathway is likely to be reduced in women carrying the rare *KCNG4* SNP rs140124801 allele.

Heterozygous K~V~6.4-Met419 Acts as a Dominant-Negative Mutation to Abolish Wild-Type Function {#sec2.9}
----------------------------------------------------------------------------------------------

The SNP rs140124801 minor allele identified in healthy women not requiring analgesia during their first labor was always in a heterozygote state. We wanted to find out whether this heterozygous state has as much of an effect on K~V~2.1 as the homozygous state used in our sub-cellular localization and electrophysiology studies or whether the effect size was between homozygous K~V~6.4 and homozygous K~V~6.4-Met419. Indeed, our findings of reduced labor pain are compatible with the minor allele of rs140124801 having a dominant-negative effect or a reduced-dosage effect but incompatible when acting as a recessive. K~V~2.1 was co-transfected into HEK293 cells with equimolar concentration of K~V~6.4 and K~V~6.4-Met419 and stained for HA-K~V~6.4 and the membrane marker Na^+^/K^+^ ATPase. We found significant co-localization of K~V~6.4 with Na^+^/K^+^ ATPase at the plasma membrane but no evidence of trafficking to the cell membrane for homozygote K~V~6.4-Met419 or when K~V~6.4 and K~V~6.4-Met419 were co-transfected ([Figures 4](#fig4){ref-type="fig"}A and 4B).Figure 4Sub-cellular Localization and Electrophysiology Analysis of the Dominant-Negative Effect of Human K~V~6.4-Met419(A) HEK293 and HeLa cells (separate experiments) were transfected with K~V~2.1 and wild-type K~V~6.4, K~V~6.4-Met419, or equimolar concentrations of K~V~6.4/K~V~6.4-Met419. Cell membranes were stained with Na^+^/K^+^ ATPase (red channel) and HA-tagged K~V~6.4 (green channel). HA-tagged K~V~6.4 localized to the cell membrane, showing significant co-localization with Na^+^/K^+^ ATPase. K~V~6.4-Met419 and K~V~6.4/K~V~6.4-Met419 co-expression showed cytoplasmic retention of K~V~6.4 and no evidence of co-localization with Na^+^/K^+^ ATPase. The graphs display the profiles of signals for the membrane and K~V~6.4.HA along the plane of the white line in the merged image. Note that the red and green signal co-localize in the K~V~6.4 experiment and are distinct in the K~V~6.4-Met419 and heterozygote experiment. Scale bars indicate 20 μm.(B) Quantification of Pearson's co-localization co-efficient between K~V~6.4.HA and Na^+^/K^+^ ATPase under each experimental condition. For each condition, at least 17 cells were counted from three independent experiments.(C) V~0.5~ act from inactivation protocols shown in [Figures 1](#fig1){ref-type="fig"}D--1G. Co-expression of K~V~6.4 and K~V~6.4-Met419 with K~V~2.1 failed to evoke a shift in the voltage dependence of inactivation.Bars indicate mean values, error bars indicate SEM, n = 9--15, ^∗∗∗^p \< 0.001. The statistics in (B) and (C) represent one-way ANOVA with Bonferroni's multiple comparisons test.

Similarly, co-transfection of equimolar K~V~6.4 and K~V~6.4-Met419 with K~V~2.1 produces electrophysiological properties comparable with transfection of K~V~2.1 only; i.e., co-expression of the minor allele variant prevented the hyperpolarizing shift of the voltage dependence of inactivation produced by the major allele variant ([Figure 4](#fig4){ref-type="fig"}C).

In addition, we investigated whether K~V~6.4-Met419 might affect heterotetramerization with K~V~2.1. Co-immunoprecipitation experiments in transfected HEK293 cells demonstrate that, unlike K~V~6.4, K~V~6.4-Met419 is unable to bind to K~V~2.1 ([Figures S6](#mmc1){ref-type="supplementary-material"}A and S6B). When K~V~6.4 is tagged but co-expressed with K~V~6.4-Met419 (untagged), there is notably reduced binding of K~V~6.4 to K~V~2.1 ([Figure 5](#fig5){ref-type="fig"}A). Similarly, by immunofluorescence analysis, the presence of untagged K~V~6.4-Met419 suffices to disrupt K~V~6.4 trafficking to the plasma membrane ([Figures 5](#fig5){ref-type="fig"}B and 5C).Figure 5Effects of K~V~6.4-Met419 on K~V~2.1 Heterotetramerization(A) Wild-Type K~V~6.4 co-immunoprecipitates with K~V~2.1 when co-expressed in HEK293 cells (pulling down with K~V~2.1 or HA-tagged K~V~6.4). K~V~6.4-Met419 disrupts binding to K~V~2.1, and there is significantly reduced binding of HA-tagged K~V~6.4 to K~V~2.1 when co-expressed with untagged K~V~6.4-Met419.(B) K~V~6.4 traffics to the plasma membrane less efficiently when co-expressed with untagged K~V~6.4-Met419, indicating a dominant-negative effect. Scale bars indicate 10 μm.(C) Quantification of K~V~6.4 membrane localization by Pearson's coefficient, assessing co-localization of HA and the Na^+^/K^+^ ATPase membrane marker. Data are from three independent experiments. Error bars indicate SEM, \*\*\*p \< 0.001

We therefore conclude that the K~V~6.4-Met419 variant acts as a dominant-negative subunit and significantly affects the function of K~V~6.4 (and, hence, K~V~2.1) in the heterozygote state identified in our cohort of women who did not require analgesia during their first labor.

Discussion {#sec3}
==========

Parturition may be physiological and widely considered to be "natural" but remains among the most painful events in life that women can experience ([@bib26]). Labor pain is a complex experience with many biopsychosocial determinants, of which visceral nociception is fundamental and necessary. Although the cellular and molecular substrates for visceral nociception are ill defined in humans, ion channels that are important regulators of uterine sensory neuron excitability may determine visceral nociception and, hence, labor pain.

Labor pain is challenging, if not impossible, to model adequately in pre-clinical laboratories. Our genetic approach in humans here was not to discover very rare Mendelian mutations that cause extreme and, hence, pathological painlessness (e.g., congenital insensitivity to pain). Instead, we sought to investigate SNPs that are more common and for which frequencies in the general population are known. We hypothesized that such SNPs would be significantly over- or under-presented in a cohort of women with a less extreme but nonetheless clinically relevant phenotype. Hence, we chose to investigate healthy nulliparous women who chose and were able to manage pain from spontaneous and uncomplicated vaginal delivery of term labor without any analgesia. In this group, there were no deficits in detection of innocuous warmth, cool, or cuff grip pressure to suggest clinically relevant sensory neuropathy. There were also no differences in cognitive test battery performance, pain-relevant personality traits, or emotional function compared with controls. However, these women demonstrate increased pain and tolerance thresholds to a range of noxious stimuli and significantly so for cuff pressure pain.

Given that our painlessness phenotype is far less extreme compared with that of congenital insensitivity to pain, we did not expect that any rare SNPs discovered in this study would cause a large increase in experimental pain threshold or tolerance of all stimulus modalities. Nonetheless, there is modest evidence from a study by [@bib9] that a composite of these measures obtained just before induction of labor in singleton, term pregnancies predicts analgesic consumption, i.e., the volume of local anesthetic infused, in women who requested an epidural. We found that the cuff pressure pain threshold was robustly and very significantly increased in women who did not request any analgesic. Labor pain has visceral and somatic components caused by contractions of uterine viscus but also by sustained stretching or compression of the pelvic floor, perineum, and vagina ([@bib21]), which occur in the later stages of labor as the fetus descends and may be experienced as a continuous background pain on which rhythmic pain caused by uterine contractions is superimposed ([@bib28]). Although speculative, the hypothesis that women with high cuff pressure pain thresholds would report reduced intensity of continuous background pain during labor is testable.

Blinding was not feasible in our experiments, and social desirability bias may explain our overall findings of an increased threshold and tolerance of pain. However, such a bias might be expected to also significantly lower scores for self-reported pain-related traits, particularly pain catastrophizing ([@bib46]), but that was not observed. Our data are consistent with those from other investigators who show that scores from the PCS and Fear of Pain questionnaires do not influence self-reported or behavioral measures of labor pain ([@bib10]). Pain is a complex experience with sensory-discriminatory and affective-motivational aspects ([@bib23]). We found that the test cohort had lower short-form McGill's pain questionnaire (SFMPQ) scores that pertained to the sensory but not the affective qualities of the pain experienced during cold tolerance testing. In sum, we found an increased threshold to pain from noxious stimuli (significantly so for cuff pressure) but no differences in cognitive function, personality traits, and emotional function in women who did not require analgesics during term nulliparous labor. These findings suggest that nociceptive function is altered in these women and validate their selection to discover predisposing genetic changes in sensory neurons (nociceptors) that might influence labor pain in women, a phenotype that otherwise would confidently have been expected to be highly heterogeneous.

We detected a single SNP, rs140124801, in the gene *KCNG4*, where the rare allele had a significant over-representation compared with the general population in a cohort of 158 women who had no analgesic requirement during nulliparous labor, noting that, ideally, control allele frequencies would have been generated from a matched cohort of women who did require analgesia. There were 4 heterozygotes who possess the rare allele, and data on quantitative sensory and pain testing were available for 3 heterozygotes. We found that women who possess the rare allele showed a significantly increased cuff pressure pain threshold compared with controls ([Table S4](#mmc1){ref-type="supplementary-material"}). The rare allele of SNP rs140124801 causes a missense change, p.Val419Met, in K~V~6.4, a silent K~V~ subunit that forms heterotetramers with K~V~2 channels and modulates their function ([@bib7]). We and others show that K~V~6.4 traffics to the plasma membrane only when co-expressed with K~V~2.1 ([@bib33]). In contrast, we found that the rare allele product K~V~6.4-Met419 failed to traffic to the plasma membrane when co-expressed with K~V~2.1. Moreover, K~V~6.4-Met419 failed to induce the hyperpolarizing shift in the voltage dependence of K~V~2.1 inactivation that is observed with K~V~6.4, likely indicating that the observed currents would be conducted by K~V~2.1 homotetrameric channels.

We have found that K~V~6.4-Met419 was unable to heterotetramerize with K~V~2.1. A possible explanation for this is gained from X-ray crystallography of the K~V~2.1 homotetramer (PDB: [3LNM](pdb:3LNM){#intref0020}). Each of the four K~V~2.1 monomers contributes equally to the K^+^ ion selectivity region, which is formed by the peptide backbone carbonyl groups of the amino acids TVGYG. The side chains of valine and tyrosine from each of the four monomers fits within an aliphatic pocket of the adjacent monomer (composed of amino acids WWAIIS; [Figure 1](#fig1){ref-type="fig"}C). The rare allele of SNP, rs140124801, results in valine being changed to methionine, whose side chain is too large to be accommodated by this aliphatic pocket. This may be sufficient to stop K~V~6.4 forming a heterotetramer with K~V~2.1 and would be predicted to disrupt the close packing of the peptide backbone carbonyl groups of the ion selectivity region.

For K~V~6.4 to modulate labor pain, it needs to be expressed in an appropriate part of the sensory nervous system. We focused on uterine sensory neurons, but this does not negate the possibility that K~V~6.4 also exerts influence elsewhere in the nervous system, given that *KCNG4* mRNA is also expressed in regions of the spinal cord and brain ([Figure S6](#mmc1){ref-type="supplementary-material"}C). We observed K~V~6.4 expression in Trpv1- and Na~V~1.8-positive mouse uterine sensory neurons, consistent with the observation that sensory neurons innervating deep tissues display comparatively high Trpv1 expression ([@bib24]). Results from unbiased single-cell RNA sequencing of mouse DRG neurons obtained from cervical to lumbar levels reveal no specific coexpression of K~V~6.4 in nociceptive Trpv1/Scn10a-expressing neurons ([@bib54]). However, single-cell RNA sequencing of colonic sensory neurons identified that K~V~6.4 does co-localize with Trpv1 and Na~V~1.8 ([@bib18]), consistent with our findings here that K~V~6.4, Trpv1, and Na~V~1.8 are coexpressed in uterine sensory neurons from T12--L2 and L5--S2 DRG. Taken together, these data suggest that K~V~6.4 might be a marker for sensory neurons that innervate the viscera. Because of the restricted expression of *Kcng4* in a particular sensory neuron type, expression of K~V~6.4-Met419 is expected to reduce excitability specifically for this class of sensory neurons.

For the rare allele rs140124801 to modulate labor pain, it needs to cause a significant change in K~V~6.4-influenced neuronal activity and do so in the heterozygote state. Our electrophysiology and cell trafficking studies showed that the mutant K~V~6.4-Met419, as opposed to K~V~6.4, had no effect on K~V~2.1 function, nor was it trafficked to the plasma membrane. Transfection of K~V~6.4 into mouse sensory neurons produced a more hyperpolarized voltage dependence of inactivation for the predicted heterotetrameric K~V~2/silent K~V~ channel component of *I*~K~ than when K~V~6.4-Met419 was transfected, further supporting the hypothesis that the loss-of-function K~V~6.4-Met419 results in more K~V~2.1 activity at positive voltages. K~V~2.1 is known to contribute to after-hyperpolarization duration and intra-action potential refractory period and, thus, regulate neuronal excitability ([@bib48]). Hence, we anticipated that a K~V~6.4-Met419-induced deficit in K~V~2.1 function would likely result in fewer action potentials and, thus, less pain during periods of sustained nociceptor activity, such as that occurring with uterine contractions during labor. Although we did not observe a difference in after-hyperpolarization duration or action potential frequency between sensory neurons transfected with K~V~6.4 or K~V~6.4-Met419 (possibly because of the continual current injection used), we did find that a larger amount of current was required to cause K~V~6.4-Met419-expressing neurons to fire actions potentials and conclude that the mutation confers reduced neuronal excitability ([Figure 6](#fig6){ref-type="fig"}). Critically, we observed that K~V~6.4-Met419 has a dominant-negative effect on K~V~6.4 regarding modulation of the voltage dependence of inactivation for K~V~2.1. This result likely explains the reduction in labor pain seen in individuals in our cohort who were heterozygotes for the SNP rs140124801 rare allele. Although the results contained herein demonstrate the effect of K~V~6.4-Met419 on neuronal excitability, another way to demonstrate this would be to generate transgenic mice or use adeno-associated viruses to transduce sensory neurons innervating a specific target, as conducted recently with the knee ([@bib11]). Using mice overexpressing K~V~6.4-Met419, we hypothesize that, like humans expressing the SNP rs140124801 rare allele, these K~V~6.4-Met419 mice might have a raised threshold to acute noxious stimuli compared with wild-type mice and potentially have a reduced chronic pain phenotype, results that would align with the known roles of K~V~ channels in mouse pain behavior; for example, knockout of K~V~9.1 leads to increased basal mechanical pain and exacerbates neuropathic pain ([@bib49]).Figure 6Schematic of the Mechanism by which the Rare Allele SNP rs140124801 p.Val419Met in *KCNG4* (Encoding the K~V~ Subunit K~V~6.4) Regulates Neuronal ExcitabilityIn most individuals (left panel), visceral nociceptors capable of transducing labor pain possess a combination of homomeric K~V~2.1 channels and heteromeric K~V~2.1/K~V~6.4 channels, whereas in individuals with the rare allele SNP rs140124801 p.Val419Met in *KCNG4* (right panel), K~V~2.1/K~V~6.4-Met419 heteromers fail to traffic from the cytoplasm to the plasma membrane, resulting in a greater proportion of K~V~2.1 homomeric channels. Because of their steady-state inactivation properties, K~V~2.1/K~V~6.4 heteromers have reduced availability at more depolarized membrane potentials compared with K~V~2.1 homomers, and, thus, in nociceptors expressing K~V~6.4-Met419, there is greater K~V~2.1 homomer-mediated current at depolarized membrane potentials, which reduces neuronal excitability.

Moreover, the importance of K~V~s in regulating neuronal excitability is highlighted by a study of induced pluripotent stem cell-derived sensory neurons (iPSC-SNs) derived from a mother and son with inherited erythromelalgia (IEM) ([@bib29]). Both individuals carry the same Na~V~1.7 variant that is associated with IEM, but the frequency and duration of pain attacks differed, thus implicating further genetic variants. Whole-exome sequencing of both individuals identified a *KCNQ2* variant that encodes K~V~7.2 in the individual experiencing less pain. Interestingly, the "less pain" variant resulted in a hyperpolarizing shift in V~1/2~ for activation of the K~V~7.2-mediated M current (a major determinant of resting membrane potential \[RMP\]) and a more hyperpolarized RMP, making it more difficult for action potentials to be evoked in iPSC-SNs. Thus, this study, alongside ours, demonstrates the importance of K~V~ function in modulating neuronal excitability and pain experience.

There is a growing understanding of the distinctions between the neural pathways for pain from visceral and somatic tissues; each has evolved nociceptors that sense damage in different physical environments ([@bib3]). Our findings suggest a key role of K~V~6.4 in specifically regulating nociceptor excitability and, hence, pain in normal labor. K~V~6.4 is also expressed in other parts of the nervous system ([Figure S6](#mmc1){ref-type="supplementary-material"}C), and its expression in non-neural tissues is unknown. However, we found that women carrying the rare allele *KCNG4* managed nulliparous labor without analgesics and had higher experimental pain thresholds but were otherwise healthy without any psychological or cognitive abnormalities. Their phenotype suggests that the loss of modulatory effects of K~V~6.4 is non-pathogenic in other parts of the nervous system and non-neural tissues. If druggable, then K~V~6.4 would be a potential target for modulating labor pain without the maternal and neonatal side effects inherent in other analgesic interventions in this setting. Our data also raise the question of whether K~V~6.4 has roles in other painful visceral disorders within and outside the female genital tract. One closely related context would be primary dysmenorrhea, which is characterized by severe pain associated with uterine contraction during menstruation ([@bib20]). Further development of selective K~V~6.4 pharmacological agents is required to fully probe the role of K~V~6.4 in visceral pain.
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REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Anti-HA mouse monoclonalBiolegendCat\# 12B12, \#MMS-101P; RRID: [AB_2801249](nif-antibody:AB_2801249){#interref55}Anti-K~V~2.1 rabbit polyclonalAlomoneCat\# APC-012; RRID: [AB_2040162](nif-antibody:AB_2040162){#interref60}Anit-K~V~2.1 mouse monoclonalAbcamCat\# ab192761; RRID: [AB_2750677](nif-antibody:AB_2750677){#interref65}Anti-HA rabbit monoclonalCell SignalingCat\# C29F4 \#3724: RRID: [AB_10693385](nif-antibody:AB_10693385){#interref70}Anti-Na^+^/K^+^ ATPase rabbit monoclonalAbcamCat\# Ab76020; RRID: [AB_1310695](nif-antibody:AB_1310695){#interref75}Anti β-actin mouse monoclonalSigma AldrichCat \# A2228; RRID: [AB_476697](nif-antibody:AB_476697){#interref80}Anti-mCherry rat monoclonalThermoFisherCat \# M11217; RRID: [AB_2536611](nif-antibody:AB_2536611){#interref85}**Chemicals, Peptides, and Recombinant Proteins**TrypsinSigma-AldrichT4799CollagenaseSigma-AldrichC5138Bovine serum albuminSigma-AldrichB2064Fast BluePolysciences17740Trypsin from Bovine PancreasSigma-AldrichT9935Collagenase, Type 1ASigma-AldrichC9891CapsaicinSigma-AldrichM2028Stromatoxin-1AlomoneSTS-350FuGENE HD transfection reagentPromegaE2311**Critical Commercial Assays**CellsDirect One-Step qRT-PCR kitInvitrogen11753100Amaxa Mouse Neuron Nucleofactor kitLonzaVPG-1001Dynabeads Co-Immuniprecipitation KitThermoFisher14321D*Kcng4* Taqman primer-probeApplied BiosciencesMm01240890_m1*Kcnb1 Taqman primer-probe*Applied BiosciencesMm00492791_m1*Trpv1* Taqman primer-probeApplied BiosciencesMm01246300_m1*Scn10a* Taqman primer-probeApplied BiosciencesMm00501467_m1*Gapdh* Taqman primer-probeApplied BiosciencesMm99999915_g1**Experimental Models: Cell Lines**HeLaSigma Aldrich93021013HEK293Sigma Aldrich85120602**Experimental Models: Organisms/Strains**C57BL/6J miceEnvigoWild-type**Recombinant DNA***KCNG4* cDNA clone in polioIRESmCherry w/wo HA tagThis manuscriptN/AK~v~2.1 in pCAGGS-IRES2-nucEGFPGift from Prof Saitsu[@bib40]*KCNG4.Met419* cDNA clone in polioIRESmCherry w/wo HA tagThis manuscriptN/A**Software and Algorithms**R Studio Version 1.2.5036 for MacR<https://rstudio.com/products/rstudio/>pClamp (v10.3)Molecular DevicespClamp (v10.3)Prism (v8)GraphPadPrism (v8)PatchmasterHEKAheka.comFitmaster v2x90.4HEKAheka.comIgor pro v6.37WaveMetricswavemetrics.comPatcher's Power ToolsMax-Planck-Institut<https://www3.mpibpc.mpg.de/groups/neher/index.php?page=aboutppt>Step One version 2.3Applied BiosystemsN/A**Other**Poly-D-lysine and laminin coated coverslipsBD Biosciences354087Nucleofector IIbLonzaAAB-1001Multiclamp 700A amplifierMolecular DevicesN/ADigidata 1440AMolecular DevicesN/ARapid change perfusion systemIntracelEVH-9EPC-10 amplifierHEKAN/APipette pullerSutter InstrumentsP-97Lebovitz L015 GlutamaxThermo Fisher Scientific31415029Poly-D-lysine coated coverslipsBD Biosciences354086SUPERase-inhibitorAmbionAM2696
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### Lead Contact {#sec5.2.1}

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Ewan St John Smith (mailto:<es336@cam.ac.uk>).

### Materials Availability {#sec5.2.2}

Plasmid constructs generated in this study will be made available upon request, subject to ethical restrictions and Material Transfer Agreements.

### Data and Code Availability {#sec5.2.3}

Clinical datasets supporting [Tables 1](#tbl1){ref-type="table"}, [S2](#mmc1){ref-type="supplementary-material"}, and [S3](#mmc2){ref-type="supplementary-material"} and [Figure S2](#mmc1){ref-type="supplementary-material"} are available upon request, subject to ethical restrictions.

Fully anonymized SNP data supporting the exome analyses ([Figure 1](#fig1){ref-type="fig"}A) are provided in [Table S3](#mmc2){ref-type="supplementary-material"}

Experimental Model and Subject Details {#sec5.3}
--------------------------------------

### Human case ascertainment and recruitment {#sec5.3.1}

Labour pain is a complex experience and difficult to quantify ([@bib2]). Epidurals and inhalational analgesia are currently the most effective forms of pain relief in labor ([@bib19]). Hence the rate of epidural use is a recognized surrogate measure for pain in clinical trials that assess the effectiveness of other forms of analgesia in labor ([@bib22]). The use of inhalational analgesia is far commoner, particularly in nulliparous parturients where labor is considered more painful. A UK survey suggests that Entonox® use in labor at 80% and first-time mothers were more likely to use labor analgesia ([@bib32]). Hence, the phenotype for less painful labor was defined operationally as nulliparous parturients who did not request nor use epidural, inhalational or opioid-based analgesia. This behavioral definition would have captured individuals with *SCN9A* channelopathy who reported entirely painless labor ([@bib16]).

The studies commenced in October 2012 after National Research Ethics Service and Human Research Authority approval (Reference: 12-EE-0369) was granted. For the first study (Study A), potential participants were identified based at maternity units in the United Kingdom and invited via post to contact the research team. The post included an information sheet stating that the study sought "to use genetic analysis to look for variations in genes in women who do not feel as much pain as might be expected during childbirth, and determine whether such variation in pain experience might be related to genetic differences' and the invitation was for women that 'have had a baby and according to our records, you required minimal or no pain relief during the birth of your first child."

All potential participants who contacted the research team were further screened via telephone interview for eligibility ([Table S1](#mmc1){ref-type="supplementary-material"}). Eligible participants were posted study information and a saliva sampling kit (Oragene®-DNA, OG-500, Genotek), with a self-addressed return envelope. Participants did not receive any financial incentive for the genetic study.

In the second study (Study B), women who had consented to the genetic study and for whom exome sequencing was successful were invited to the Cambridge NIHR Clinical Investigation Ward for further study. Those who were eligible ([Table S1](#mmc1){ref-type="supplementary-material"}) and consented to participate comprised the test cohort.

Women who met the study criteria but who required analgesia during labor served as case controls. Controls were informed via participant information leaflet we have *"identified women who did not use painkillers during the birth of their first child. However, we are still unsure whether they are actually less sensitive to pain. In order to find out, we need to test their pain sensitivity and compare their results to women who did used an Epidural or Entonox (gas and air) for pain relief during their first labour"*. Controls were selected to match age at delivery of first-born, location of maternity unit and age at study visit. A total of 1029 invitations were sent by post. Where available, data on birth weight of baby and head circumference were recorded. The age range for the test and control cohorts were 27 to 48 years, and 28 to 44 years respectively ([Table 1](#tbl1){ref-type="table"}).

Participants were reimbursed up to maximum of 25GDP for time in addition to travel expenses for the two-hour visit. All participants and the researchers who communicated directly with them remained blind to genotype during the study.

### Cell lines and culture conditions {#sec5.3.2}

HEK293 and HeLa cells were cultured in 90% Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin-streptomycin (pen-strep), and 2 mM L-glutamine at 37°C, 5% CO~2~, 100% humidity. Transfections were carried out using FugeneHD transfection reagent (Promega) according to the manufacturer's protocols. For co-expression studies, cloned K~V~2.1 and K~V~6.4 constructs were transfected at a ratio of 1:2. Cells for experiments were plated out on glass coverslips for immunostaining or 35 mm plastic dishes for electrophysiological recordings, 1-2 days prior to the experiment.

### Animals {#sec5.3.3}

Adult C57BL/6J mice (Envigo), male and female, aged between 8 to 12 weeks, were conventionally housed in groups of 4-5 with nesting material and a red plastic shelter and various enrichment toys; the holding room was temperature controlled (21°C) and mice were on a 12-hour/light dark cycle with food and water available *ad libitum.* Work was regulated under the Animals (Scientific Procedures) Act 1986 Amendment Regulations 2012 following ethical review by the University of Cambridge Animal Welfare and Ethical Review Body.

Method Details {#sec5.4}
--------------

### Clinical questionnaires, cognitive and sensory testing {#sec5.4.1}

A single research assistant in the same temperature-controlled room conducted all assessments. Participants were seated for the assessment and rest breaks were provided between assessments to minimize fatigue. Instructions for each assessment were read from a written script. These assessments were completed in the following sequence: (1) questionnaires administered on paper Hospital Anxiety and Depression Scale (HADS) ([@bib56]), Pain Catastrophizing Scale (PCS) ([@bib46]), Multidimensional Health Locus of Control Scale (MHLC) ([@bib44]) and Life Orientation Test-Revised (LOTR) ([@bib41]), (2) quantitative sensory testing (QST) to determine stimulus detection, pain and tolerance thresholds, and (3) computerized cognitive assessments implemented on CANTAB® (Cambridge Cognition, UK) ([@bib37]). Hospital Anxiety and Depression Scale (HADS) ([@bib56]), Pain Catastrophizing Scale (PCS) ([@bib46]), Multidimensional Health Locus of Control Scale (MHLC) ([@bib44]) and Life Orientation Test-Revised (LOTR) ([@bib41]).

### Cambridge Neuropsychological Test Automated Battery (CANTAB) {#sec5.4.2}

The cognitive assessments were drawn from the Cambridge Neuropsychological Test Automated Battery (CANTAB) (<https://www.cambridgecognition.com/>). The computerised tests required finger-tap responses via touchscreen and are largely independent of verbal instruction. CANTAB software was deployed on an XGA-touch panel 12-inch monitor (Paceblade Slim-book P120; PaceBlade Technology). The sequence of tasks employed in the study was as follows: Motor Screening Task (MOT), Spatial Working Memory (SWM), Rapid Visual Information Processing (RVIP), Intra- Extra-Dimensional Set Shift (IED) and One-Touch Stockings of Cambridge (OTS). Descriptions of each task are provided below. All tasks were performed using the index finger of the dominant hand.

### Motor Screening Task (MOT) {#sec5.4.3}

Colored crosses are presented in different locations on the screen, one at a time. The participant must select the cross on the screen as quickly and accurately as possible. Outcome measures are (a) mean latency and (b) mean error, which reflect accuracy.

### Spatial Working Memory (SWM) {#sec5.4.4}

The task assesses ability to retain spatial information and manipulate items in working memory. It is considered a sensitive measure of frontal lobe and executive dysfunction. This is a self-ordered task which also assesses heuristic strategy. Several colored squares (box) are displayed in random locations on the touch screen. There is pre-set number of boxes with a blue token. The participant taps on a box to uncover a blue 'token' and place that token into a 'bin'. The participant must remember which box has been tapped or emptied. The number of boxes is gradually increased until the participants is searching for tokens in a total of eight boxes. The color and position of boxes used are changed from trial to trial to discourage use of stereotyped search strategies. Outcome measures are (a) strategy, for which the fully efficient strategy would result in no boxes being revisited. A high score represents poor use of this strategy and a low score equates to effective use, and (b) total errors, which is the number of times a box is selected that cannot contain a blue token and therefore should not have been visited by the subject.

### Rapid Visual Information Processing (RVP) {#sec5.4.5}

A white box is shown in the center of the screen, inside which digits from 2 to 9 appear in a pseudo-random order, at the rate of 100 digits per minute. Participants are asked to detect target sequences of digits (for example, 2-4-6, 3-5-7, 4-6-8) and respond by tapping on a button-box as quickly as possible. Outcome measures are (a) sensitivity index A', which reflects how good the subject is at detecting target sequences, regardless of error tendency A score close to +1.00 indicates that a high true positive rate, and (b) response criterion B', which reflects the tendency to respond regardless of whether the target sequence is present. A score close to +1.00 indicates a high true negative rate.

### Intra-Extra Dimensional Set {#sec5.4.6}

This task assesses visual discrimination and attentional set formation maintenance, shifting and flexibility of attention. IED task requires participants to learn the rule and select the correct icon (a specific shape or line). The task builds in complexity as distractors are added and the rule changes. The rule changes are both intra-dimensional (e.g., shapes are still the relevant set, but a different shape is now correct) and extra-dimensional (e.g., shapes are no longer the relevant set, instead one of the line stimuli is now correct). Outcome measures are (a) total errors (adjusted), which is a measure of the participant's efficiency. While she may pass all nine stages, a substantial number of errors may be made in doing so. The errors are adjusted to account for those who fail at any stage of the test and hence have had less opportunity to make errors, (b) number of stages completed, and (c) total trials (adjusted), which is the number of trials completed on all attempted stages for each stage not attempted due to failure at an earlier stage.

### One Touch Stockings of Cambridge {#sec5.4.7}

This task is a test of executive function, based upon the Tower of Hanoi. The participant is shown two displays containing three colored balls. The displays are presented in such a way that they can be easily perceived as stacks of colored balls held in stockings suspended from a beam. The participant is shown how to move the balls in the lower display to copy the pattern in the upper display and completes one demonstration problem, where the solution requires one move. The participant must then complete three further problems, one each requiring two moves, three moves and four moves. Next the participant is shown further problems and must work out mentally the number of moves the solutions require and then select the appropriate box at the bottom of the screen to indicate their response. Outcome measures are (a) mean choice to correct, which is the mean number of attempts to the correct response, and (b) mean latency to correct, which is the overall latency (time required) to the correct response.

### Quantitative sensory testing {#sec5.4.8}

Stimulus detection and pain thresholds for heat and cold were determined by applying a 3x3 cm^2^ thermode on the volar surface of the non-dominant mid-forearm (TSA, Medoc, Israel). The procedure was adapted from a clinical research protocol ([@bib39]), for which the research assistant received formal training (Universitsmedizin Mannheim). Stimulus detection and pain thresholds were determined using increasing or decreasing temperature ramp of 1°C.s^-1^ from a baseline temperature of 32°C, with low and high safety cut-offs at 0 and 50°C respectively. Participants were instructed to click on a button when they first experience the required sensations. Four trials each with an inter-trial interval of 10 s were employed to assess heat and cold stimulus detection thresholds. Three trials with a longer inter-trial interval of 30 s were employed for heat and cold pain thresholds to minimize risks of burn.

Pressure detection and pain threshold were determined by cuff algometry ([@bib50]) applied to the dominant upper arm. The circumference of the upper arm was measured to determine the appropriate sphygmomanometer cuff size. A digital metronome (Korg MA-1, UK) was used to guide manual inflation of the cuff at 10 mmHg every 5 s. The participant was instructed to verbally report when the point the cuff was felt to be 'just gripping' and when the gripping became just about painful, at which point the cuff pressure was rapidly released. The pressures at thresholds were recorded. The participant was then asked to indicate when all evoked sensation in the arm had resolved. The entire procedure was repeated thrice.

Pain tolerance was measured as latency to withdrawal from immersion of hand in a cold water bath (3°C) ([@bib30]). The participant was instructed to immerse her non-dominant hand and wrist into a circulating cold-water bath (RW2025G, Medline Scientific UK) and to withdraw the hand *ad libitum* when pain became intolerable. The maximum duration of cold-water immersion allowed was 180 s, after which the participant was told to remove her hand from the water bath. All participants were told that there was a maximum allowable duration for immersion for safety but not the exact duration to avoid anticipatory effects.

The skin temperature of the hand dorsum was measured (NC 150, Microlife, Switerland) within 60 s pre-immersion and 10 s post-immersion (after the hand was wiped dry). Participants were then asked to rate peak intensity of pain during immersion using a 100mm visual analog scale (VAS) with the left and right anchors labeled as 'no pain' and 'worst imaginable pain' respectively. They were also asked to estimate when the intensity of pain peaked during the period of immersion (100mm VAS; 0mm and 100mm represented the times of hand immersion and hand withdrawal respectively). Finally, participants completed the Short-Form McGill Pain Questionnaire (SQ-MPQ). The questionnaire comprises 15 pain descriptors: 11 pertain to sensory-discriminatory aspects (e.g., 'hot-burning'), and the rest pertained to affective-motivational (e.g., 'cruel-punishing') of the pain experienced during cold-water immersion of the hand ([@bib27]).

### Genetic analysis of non-synonymous functional single nucleotide polymorphism alleles {#sec5.4.9}

For the genetic analysis of the discovery cohort we used the fSNPd approach ([@bib45]). In brief, the hypothesis is that some individuals with a defined phenotype (in our case reduced labor pain inferred by the absence of analgesia requirement during labor) could have genetic predisposition(s) that explain their difference in phenotype. To be detected, such a genetic predisposition would have to be dominantly inherited and often penetrant: this is the case with many known autosomal dominant Mendelian genetic disorders such as Tuberose Sclerosis and Neurofibromatosis type 1 where the phenotype is variable (and can be incomplete) despite an individual carrying the known pathogenic familial mutation. The fSNPd approach further hypothesizes that the phenotype will not be caused by very rare genetic mutations, but by the rare alleles of known SNPs where the allele difference is protein changing. Examples of such SNPs exist that only cause a human phenotype when the heterozygous individual is exposed to a specific environmental insult or trigger, e.g., aminoglycoside induced deafness ([@bib36]) and SNPs rs267606617 and rs267606618; and carbamazepine associated toxic epidermal necrolysis and rs3909184 ([@bib12]).

An exome analysis was performed on the genomic DNA of the 100 individuals of the discovery cohort by Beijing Genomics Institute using the Agilent 51M kit sequenced to an average of 50-fold coverage, as previously described ([@bib31]). Such an analysis does not include all coding exons of all human genes, and for this reason SNPs in some genes are not assessed, and other SNPs were not assessed in all individuals in the discovery cohort ([@bib45]). The exome v*cf.*, bam and bam.bai files were iteratively analyzed extracting data on all SNP in or near to exons, including the depth and quality of the sequence data, and the alleles detected ([@bib45]). For each SNP the allele frequencies were compared to normal values, and deviations assessed for significance using a Chi-square test with two tails and Yates correction. The resulting *P value*s were subject separately to a Bonferroni correction and false discovery rate (FDR) correction, as approximately 100,000 SNPs were assessed in our fSNPd method. We then filtered only for clear-cut protein changing SNPs (missense mutations predicted deleterious by SIFT, nonsense mutations, splice site mutations, start codon mutations, and within-exon deletions and duplications), as such changes are potentially more amenable to function tests of pathogenicity; reducing from 18,106 SNPs prior to SIFT and pathogenicity analysis to 3,596 afterward. We then further filtered only for SNPs within ion channel genes, as members of this group of genes have already been implicated in Mendelian pain disorders, and testing techniques for ion channel function are well established; resulting in 28 SNPs ([@bib43]). For all SNPs, especially those whose rare allele frequency is \< 5%, geographical and ethnic differences must be considered; rs140124801 has a rare allele frequency in EVS of 0.0051 (cohort size 6500), in gNOMAD Europeans = 0.0072 (cohort size 18,878), 1000 Genomes = 0.0048 (cohort size 2,504), and our population were Caucasian and predominantly born in the United Kingdom.

In the discovery cohort we assessed all individual bam files with the Integrated Genome Viewer to determine which rs140124801 alleles were present, blind of the fSNPd results. All individuals predicted to have the rs140124801 rare allele were Sanger sequenced and complete concordance was found. Primers were designed with Primer3 and are available on request. Genomic DNA of the 58 individuals in the replication cohort was Sanger sequenced to determine the SNP rs140124801 allele frequencies. The allele frequency and number of heterozygotes of rs140124801 was assessed in combined cohort of discovery and replication by Chi^2^ test with two tailed and Yates correction (for small numbers), using the more conservative control population allele frequency of 0.0072 for heterozygote carriers.

We assessed the effects on protein sequence and protein function of the *KCNG4* SNP rs140124801 alleles by use of bioinformatic resources within the Human Genome Browser, NCBI BLASTP for protein sequence comparisons and Conserved Domains (CD search) for detecting if the amino acid change occurred within a known protein domain and SIFT for pathogenicity prediction.

### Modeling of KCNG4 alleles on the K~v~2.1/K~v~6.4 heterotetramer {#sec5.4.10}

We used the X-ray crystallography derived structure of rat K~V~2.1 homotetramer (RCSB Protein Data Bank ID: 3LNM) to model the effects of the rare allele of rs140124801 ([@bib47]). Rat and human subunits form both K~V~2.1 homotetramers and 3:1 K~V~2.1:K~V~6.4 heterotetramers. Rat was the closest species to humans with a published K~V~2.1 protein structure. Rat and human K~V~2.1 proteins are 94% identical and 79% identical for K~V~6.4. However, restricting the alignment to the 78 amino-acid region physically adjacent to the K^+^ selectivity filter (the pore loop from transmembrane region 5 to transmembrane region 6, which includes the K^+^ selectivity filter) rat and human K~V~2.1, they are identical and rat and human K~V~6.4 is 96% identical (with no amino acid changes in the aliphatic pocket or selectivity filter).

We used structure 3LNM and the Cn3D software ([@bib51]) to examine the K^+^ selectivity filter of the K~V~2.1 homotetramer to look at the sites of interaction of each of the four individual K~V~2.1 proteins, and produced images where proteins and individual amino acids were identifiable, or could be omitted from the whole tetrameric structure.

The K^+^ ion selectivity filter is formed by the peptide backbone carbonyl groups of the amino acids TVGYG of each of the four K~V~ subunits. This forms a narrow central channel through which potassium ions (K^+^) can flow out of the cell. Each K~V~ subunit forms an identical quarter of the tetramer structure about the selectivity filter region central pore. The K~V~2.1 homotetramer model reveals the side chains of the Valine and Tyrosine of each subunit selectivity filter TVGYG protruding into a highly conserved "aliphatic pocket" (with canonical sequence WWAIIS; see [Figure 1](#fig1){ref-type="fig"}C) in the adjacent K~V~ subunit. In this model the Valine-419 of K~V~6.4 can be accommodated identically compared with the equivalent Valine-374 of K~V~2.1. However, the larger aliphatic side chain of 419-Methionine in the K~V~6.4 SNP would not be able to be accommodated within the aliphatic pocket, and hence would disrupt the ion selectivity region of the K~V~2.1/2.1/2.1/6.4 heterotetramer.

### DNA constructs and antibodies {#sec5.4.11}

A full-length human *KCNG4* cDNA clone was purchased from Source bioscience (IRCMp5012B0629D) and cloned in-house into a pcDNA3 based expression plasmid (CMV-genex-polioIRESmCherry) both with or without a C-terminal HA tag. The p.Val419Met mutation was introduced by site-directed mutagenesis (Stratagene) according to the manufacturer's protocols and sequences of the plasmids were confirmed by Sanger Sequencing. The clone expressing K~V~2.1 alongside a nuclear GFP reporter in the pCAGGS-IRES2-nucEGFP vector has been described previously ([@bib40]) and was a kind gift from Prof. Hiromoto Saitsu.

Antibodies used were anti-HA mouse monoclonal (12B12, \#MMS-101P, Biolegend), anti-Na^+^/K^+^ ATPase rabbit monoclonal (ab76020, Abcam), anti-mCherry rat monoclonal (M11217), anti-β-actin mouse monoclonal (a2228, Sigma), anti-K~V~2.1 rabbit polyclonal (APC-012, Alomone), anti-K~V~6.4 mouse monoclonal (N458/10, NeuroMab), anti-K~V~2.1 mouse monoclonal (K89/34, ab192761, Abcam), and anti-HA rabbit monoclonal (C29F4 \#3724, Cell Signaling).

### Immunofluorescence analysis and confocal microscopy {#sec5.4.12}

HEK293 and HeLa cells were cultured on poly-L-lysine coated coverslips and transfected as described above. 48-hours after transfection, cells were fixed by 10 minutes incubation in 4% paraformaldehyde. Cells were permeabilized by 10 minutes incubation in 0.3% Triton X-100 solution followed by 30 minutes at room temperature in 5% BSA solution. Alternatively, when staining for Na^+^/K^+^ ATPase, cells were fixed and permeabilized by emersion in ice cold methanol. Fixed cells were then stained with primary antibodies for 1 hour in 5% BSA and fluorescent secondary antibody also for 1 hour. Secondary antibodies used were Alexa Fluor 488 donkey anti-mouse, Alexa Fluor 546 goat anti-rabbit, Alexa Fluor 546 donkey anti-mouse, Alexa Fluor 633 goat anti-mouse (all from Life Technologies). Coverslips were mounted onto glass slides using Prolong Diamond Antifade Mountant with DAPI (Molecular Probes). Cells were visualized with an LSM880 confocal microscope.

### Co-immunoprecipitation {#sec5.4.13}

HEK293 cells were transfected with K~V~2.1 and K~V~6.4 plasmid constructs as described in the associated figures, and harvested after 3 days. Co-immunoprecipitation was carried out using the Dynabeads Co-Immuniprecipitation Kit (Life Technologies) according to the manufacturers protocols. Antibodies used were anti-HA mouse monoclonal (12B12, \#MMS-101P, Biolegend), anti-K~V~2.1 rabbit polyclonal (APC-012, Alomone), anti K~V~2.1 mouse monoclonal (K89/34, ab192761, Abcam), and anti-HA rabbit monoclonal (C29F4 \#3724, Cell Signaling). IP buffer supplied in the kit was supplemented with 80mM NaCl.

### Electrophysiological characterization of KCNG4 SNP rs140124801 alleles and KCNB1 in HEK293 cells {#sec5.4.14}

Whole-cell recordings from transfected HEK293 cells were performed using 1-2.5 MΩ resistance fire-polished borosilicate glass electrodes filled with an internal pipette solution containing (in mM): KCl (110), K~4~-BAPTA (5), HEPES (10), MgCl~2~ (1), K~2~ATP (5), pH 7.3, 281 mOsm/kg. Cells were continuously superfused with bath solution containing (in mM): NaCl (145), KCl (4), HEPES (10), D-glucose (10), CaCl~2~ (1.8) MgCl~2~ (1), pH 7.4, 300 mOsm/kg, at room temperature (20-24°C). Potassium currents (*I*~K~) were recorded in voltage clamp mode using an Axopatch 200B connected through a Digidata 1440A A/D converter and pCLAMP software (version 10, Axon Instruments). The calculated linear leakage current was digitally subtracted offline for all current measurements. Potassium currents were elicited by step depolarisations from a holding potential of −90 mV to various test potentials. The voltage-dependence of activation was determined from tail currents recorded from a 200 ms voltage step to −60 mV following these various test potentials. The normalized tail currents were plotted against the voltage of the step depolarisations and fit with a Boltzmann function. A double pulse protocol was used to measure the voltage-dependence of steady-state inactivation. The protocol consisted of a 5 s prepulse that ranged between −110 to +40 mV from a holding potential of −90 mV followed by a 200 ms test pulse to +50 mV. Normalized currents during this test pulse were plotted against the prepulse voltage and fit with a Boltzmann function. The time course of recovery from inactivation was investigated by applying a 5 s prepulse to +20 mV from a holding potential of −90 mV and applying a 200 ms test pulse to +20 mV at various time intervals after the conditioning prepulse. Recoveries from inactivation time courses were fit to a single exponential function.

### Single-cell qRT-PCR of mouse uterus innervating sensory neurons {#sec5.4.15}

Uterus innervating sensory neurons were retrograde labeled and the mRNA transcript expression for genes of interest determined using methodology previously described for other visceral organs ([@bib18]; [@bib34]; [@bib35]). Female C57BL/6J mice (10-12 weeks) were used. Following laparotomy, 2 injections (\~2.5 μl/injection) of Fast Blue (FB: 2% in saline) were made, one into each uterine horn adjacent to the cervix. Following recovery, animals were provided a soft, glucose-enriched diet and prophylactic post-operative analgesia (buprenorphine 0.05-0.1 mg kg^-1^). After 5-8 days, mice were killed by cervical dislocation and two primary cultures made from DRG T12-L2 (TL) and L5-S2 (LS), respectively. Dissected DRG were incubated in Lebovitz L-15 Glutamax (Thermo Fisher Scientific, UK) media containing 6 mg ml^-1^ bovine serum albumin (BSA, Sigma-Aldrich) and 1 mg ml^-1^ collagenase type 1A (Sigma-Aldrich, UK) for 15 min at 37°C in 5% CO~2~. After a further 30 min incubation in L-15 media containing 1mg ml^-1^ trypsin (Sigma-Aldrich) and 6 mg ml^-1^ BSA, ganglia were triturated and dissociated cell-containing supernatant collected by repeat brief centrifugation (5 × 500 *g*). TL and LS neurons were plated on poly-D-lysine coated coverslips (BD Biosciences, UK) and incubated in L-15 growth media (containing 2% penicillin/streptomycin, 24 mM NaHCO~3~, 38 mM glucose and 10% fetal bovine serum). Fluorescently labeled FB-positive cells were picked manually by pulled glass pipette into 9 μL mastermix (containing 5 μL CellsDirect 2 x reaction buffer (Invitrogen, UK), 2.5 μL 0.2 x primer-probe mix against genes of interest, 0.1 μL SUPERase-in (Ambion, USA), 1.2 μL TE buffer (Applichem, Germany) and 0.2 μL Superscript III Reverse Transcriptase-Platinum Taq mix (Invitrogen, UK)), bath samples were collected as negative controls and all samples immediately frozen on dry ice. Prior to 1:5 dilution in TE buffer, reverse transcription and preamplification of cDNA was performed by thermal cycling (50°C for 30 min, 95°C for 2 min, then 24 cycles of 95°C for 15 s, 60°C for 4 min). Gene-specific Taqman qPCR assays were then run (Taqman Assay ID: *Kcng4*, Mm01240890_m1; *Kcnb1*, Mm00492791_m1; *Trpv1*, Mm01246300_m1; *Scn10a*, Mm00501467_m1; *Gapdh*, Mm99999915_g1; Applied Biosystems) with the following thermal cycling protocol (50°C for 2 min, 95°C for 10 min, then 40 cycles of 95°C for 15 s, 60°C for 1 min). The expression of glyceraldehyde-3-phosphate dehydrogenase (*Gapdh*) acted as an internal positive control and was present in all single-cell RT-PCR products and absent in bath control samples. 15 uterine sensory neurons per region (TL and LS) per mouse (N = 3) were collected. In total, 90 neurons were collected, and photos taken for analysis of cell diameter. qPCR products were detected in 89 neurons and quantitative assessment of gene expression was determined by quantification cycle values less than the threshold of 35 considered positive.

### Whole-cell patch-clamp recordings {#sec5.4.16}

Primary DRG cultures from C57BL/6J mice (8-10 weeks) were generated using the methodology described for single-cell qRT-PCR experiments with the following exceptions. From each mouse, DRG T10-S1 were dissected and pooled into a single primary culture. After trituration, in order to purify the DRG culture to improve transfection efficiency, dissociated cells were subjected to a 3.5% BSA (in L-15 media) density gradient centrifugation (20 mins at 20 *g*) and the supernatant discarded. The remaining purified dissociated neurons were washed once in L-15 growth media before resuspension in 100 μl of Mouse Neuron Nucleofector solution (Amaxa Mouse Neuron Nucleofector Kit, Lonza, UK) containing 4.5 μg plasmid of either wild-type K~V~6.4 or K~V~6.4-Met419 in a CMV-KCNG4-polioIRESmCherry expression cassette. Incorporation of the plasmid was achieved by electroporation (Program O-0005; Nucleofector IIb, Lonza, UK) and cells plated on poly-D-lysine/laminin coated coverslips (BD Biosciences, UK) and incubated at 37°C in 5% CO~2~ and L-15 growth media. Electrophysiology experiments were conducted 48-hours post-transfection, neurons positive for mCherry fluorescence were selected following excitation with a 572 nm LED (Cairn Research, UK).

To assess voltage-gated K^+^ currents, patch pipettes were pulled using a P-97 pipette puller (Sutter Instruments, USA) with typical resistances of 3-5 MΩ and back-filled with the pipette solution containing (in mM): KAspartate (110), KCl (30), MgCl~2~ (2), CaCl~2~ (1), Na~2~ATP (5), EGTA (2), cAMP (0.1), HEPES (10), pH 7.4. Recordings were obtained using a Multiclamp 700A amplifier (Molecular Devices, USA) in the voltage-clamp mode and digitised using a Digidata 1440A (Molecular Devices). Voltage errors were minimized using 70% series resistance compensation. Mouse neurons were continuously superfused with the bath solution containing (in mM): N-methyl-D-glucamine (NMDG; 140), KCl (5), MgCl~2~ (1), CaCl~2~ (1.8), glucose (10), HEPES (5), pH 7.4. The osmolality of both solutions was adjusted to 300-310 mOsm. Cells with series resistance values greater than 15 MΩ were omitted from analysis.

*I*~K~ activation and inactivation protocols ([Figures 3](#fig3){ref-type="fig"} and [S5](#mmc1){ref-type="supplementary-material"}) were applied after achieving whole-cell rupture. Using a rapid change perfusion system (Intracel EVH-9, UK), 100 nM Stromatoxin-1 (Alomone, Israel) in bath solution was applied to the cells for 3 minutes prior to repeating activation and inactivation protocols. Thus ScTx-sensitive *I*~K~ was determined by subtraction of the post-ScTx *I*~K~ from the pre-ScTx *I*~K~ in pClamp software (Molecular Devices). The voltage-dependence of *I*~K~ activation was fitted with the following Boltzmann equation: y = *t* / (1 + exp((V~50~ -- E)/*k*)), where E is the applied voltage, V~50~ is the voltage at which 50% of the channels are activated, *t* is the top of the curve, and *k* is the slope factor. While the voltage-dependence of *I*~K~ inactivation was fitted with the sum of two Boltzmann equations: y = (*t*F / (1 + exp((~1~V~50~ - E) /~1~*k*)) + (t(1 - F) / (1 + exp((~2~V~50~-E)/~2~*k*), where E is the applied voltage, ~1~V~50~ is the voltage at which 50% of the 1st component channels are inactivated, ~2~V~50~ is the voltage at which 50% of the 2nd component channels are inactivated, *t* is the top of the curve, ~1~*k* is the slope factor for the first component and ~2~*k* for the second component, and F defines the relative component contribution.

For current clamp experiments a HEKA EPC-10 amplifier (Lambrecht, Germany) and the corresponding Patchmaster software were used. The extracellular solution contained (in mM): NaCl (140), KCl (4), MgCl~2~ (1), CaCl~2~ (2), glucose (4) and HEPES (10), pH 7.40. Patch pipettes, pulled as for *I*~K~ experiments, were filled with intracellular solution containing (in mM): KCl (110), NaCl (10), MgCl~2~ (1) EGTA (1), HEPES (10), Na~2~ATP (2), Na~2~GTP (0.5), pH 7.3. After gaining access to cells and entering current clamp mode the resting membrane potential of neurons was noted. Ramp depolarisation from 0 pA to 1 nA over a period of 1 s was first used to assess action potential threshold. A step protocol (Δ10 pA, 50 ms) was then used to confirm thresholds. The ability of neurons to fire multiple action potentials was assessed by applying a suprathreshold (2x the threshold determined by step protocol) for 500 ms. Lastly, capsaicin (1 μM in extracellular solution) sensitivity was assessed in voltage clamp mode; neurons that produced an inward current, time-locked to a 5 s application were considered responders. Only cells which fired action potentials and had a resting membrane potential less than or equal to −40 mV were taken through to analyses. Action potential parameters were measured from those evoked by the step protocol using Fitmaster software (HEKA) and IgorPro (Wavemetrics).

Quantification and Statistical Analyses {#sec5.5}
---------------------------------------

For psychometric and quantitative sensory testing, statistical analyses were performed with R Studio (Version 1.1.442). The mean and standard deviation were generated for each outcome variable for test and control cohorts. Shapiro-Wilk tests and F-tests were used assess data normality and differences in variances. Differences between the means of each outcome variable in test and control cohorts were assessed using tests for two independent samples, using Student's t test, Welch's t test or Mann-Whitney U tests when the relevant assumptions were met. The level of statistical significance was adjusted using Sidak's correction. The correction applied to multiple outcomes associated with each domain of assessments: questionnaires, CANTAB, sensory detection, pain thresholds and tolerance.

For statistical assessment of the genetic data collected in this study, enrichment of amino acid altering SNPs was assessed by exome sequencing, with exome v*cf.*, bam and bam.bai files iteratively analyzed to extract data on all SNPs in or near to exons, including the depth and quality of the sequence data, and the alleles detected ([@bib45]). For each SNP the allele frequencies were compared to normal values derived from the 1000 genomes project and exome variant server, and deviations assessed for significance using a Chi-square test with two tails and Yates correction. The resulting *P value*s were subject separately to a Bonferroni and FDR correction, as approximately 100,000 SNPs were assessed in our fSNPd method.

We then focused only on ion channels, defined as being identified by the Gene Ontology Term GO:0005216 (423 genes, which were also hand curated and checked against a Pfizer/Neusentis database that had been shared with us). There were 28 SNPs found in ion channels and each was in a different gene; there was only one detected SNP in *KCNG4*. Eight of these SNPs were then eliminated because the protein change caused by the rare allele was common in the orthologous mammalian proteins. For the remaining 20 SNPs, we determined the allele frequency of each of the by use of the Integrated Genome Viewer examining the cohort's exome bam files individually. This led to the elimination of 19 SNPs, 14 as the common allele frequency was 100% and program errors in assigning alleles within our discovery cohort had falsely appeared to show a deviation from 100%, and five because of misalignment of reads to homologous genes leading to errors in SNP allele calling and SNP allele frequency calculation.

Further statistical tests used to assess differences between K~V~6.4 and K~V~6.4-Met419 in the cellular and animal studies are unpaired t tests and ANOVA with Bonferroni's multiple comparison post hoc test, as described in the relevant figure legends. Differences between groups were considered significant at a *P value* \< 0.05, and were tested using GraphPad (Prism5.0, California, USA).
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